Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LIVN
stocks logo

LIVN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
353.52M
+9.86%
0.810
+0.05%
339.13M
+7.02%
0.891
+1.3%
374.77M
+6.32%
1.129
+7.48%
Estimates Revision
The market is revising Upward the revenue expectations for LivaNova PLC (LIVN) for FY2025, with the revenue forecasts being adjusted by 0.79% over the past three months. During the same period, the stock price has changed by 11.62%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.79%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.75%
In Past 3 Month
Stock Price
Go Up
up Image
+11.62%
In Past 3 Month
Wall Street analysts forecast LIVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIVN is 65.83 USD with a low forecast of 55.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast LIVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIVN is 65.83 USD with a low forecast of 55.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 62.750
sliders
Low
55.00
Averages
65.83
High
85.00
Current: 62.750
sliders
Low
55.00
Averages
65.83
High
85.00
Baird
Outperform
maintain
$63 -> $70
2025-11-13
Reason
Baird
Price Target
$63 -> $70
2025-11-13
maintain
Outperform
Reason
Baird raised the firm's price target on LivaNova to $70 from $63 and keeps an Outperform rating on the shares. The firm updated its model following its Investor Day which outlined its portfolio transformation to accelerate growth to 2028 and beyond.
Mizuho
Outperform
upgrade
$65 -> $70
2025-11-13
Reason
Mizuho
Price Target
$65 -> $70
2025-11-13
upgrade
Outperform
Reason
Mizuho raised the firm's price target on LivaNova to $70 from $65 and keeps an Outperform rating on the shares following the investor day. The firm upped estimates following the event.
Baird
David Rescott
Outperform
maintain
$61 -> $63
2025-11-06
Reason
Baird
David Rescott
Price Target
$61 -> $63
2025-11-06
maintain
Outperform
Reason
Baird analyst David Rescott raised the firm's price target on LivaNova to $63 from $61 and keeps an Outperform rating on the shares. The firm updated its model following results showing another quarter of double digit growth which is laying a solid foundation heading into its analyst day.
Goldman Sachs
Buy
to
Neutral
downgrade
$56 -> $55
2025-10-01
Reason
Goldman Sachs
Price Target
$56 -> $55
2025-10-01
downgrade
Buy
to
Neutral
Reason
Goldman Sachs downgraded LivaNova to Neutral from Buy with a price target of $55, down from $56. The firm believes that as the Essenz product cycle passes the halfway point, LivaNova's decelerating sales growth and slowing rate of margin expansion are likely to limit the potential for multiple expansion. Consensus estimates now more appropriately capture the company's forward outlook, the analyst tells investors in a research note.
Barclays
Matt Miksic
Equal Weight
maintain
$55 -> $58
2025-08-21
Reason
Barclays
Matt Miksic
Price Target
$55 -> $58
2025-08-21
maintain
Equal Weight
Reason
Barclays analyst Matt Miksic raised the firm's price target on LivaNova to $58 from $55 and keeps an Equal Weight rating on the shares. The firm updated the company's model to reflect management's commentary and updated 2025 outlook.
Wolfe Research
Peer Perform -> Outperform
upgrade
$60
2025-05-20
Reason
Wolfe Research
Price Target
$60
2025-05-20
upgrade
Peer Perform -> Outperform
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for LivaNova PLC (LIVN.O) is 16.23, compared to its 5-year average forward P/E of 22.48. For a more detailed relative valuation and DCF analysis to assess LivaNova PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
22.48
Current PE
16.23
Overvalued PE
32.57
Undervalued PE
12.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
15.58
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
21.46
Undervalued EV/EBITDA
9.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.80
Current PS
0.00
Overvalued PS
3.66
Undervalued PS
1.94
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LIVN News & Events

Events Timeline

(ET)
2025-11-24
09:10:45
LivaNova Secures Higher CMS Reimbursement for VNS Therapy
select
2025-11-12 (ET)
2025-11-12
15:35:42
LivaNova anticipates OSA division will reach break-even by 2029.
select
2025-11-12
15:28:27
LivaNova Unveils 2030 Financial Goals During Investor Day Event
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-03Newsfilter
LivaNova Presents Significant Seizure Reduction with VNS Therapy at AES Annual Meeting
  • Clinical Research Findings: LivaNova will present eight posters at the American Epilepsy Society Annual Meeting, highlighting the CORE-VNS study's results, which demonstrate significant seizure frequency reduction and improved quality of life for patients with Drug-Resistant Epilepsy (DRE) through VNS Therapy.
  • Data Support: The CORE-VNS study is the largest prospective multinational observational study to date, enrolling over 800 patients, providing robust data that aids clinicians in making evidence-based decisions regarding epilepsy treatment.
  • Early Intervention Impact: The research indicates that patients who received VNS Therapy after 2-3 anti-seizure medications achieved a 94% median reduction in seizure frequency at 36 months, compared to a 57% reduction for those treated after more than 10 medications, underscoring the importance of early intervention.
  • Healthcare Resource Utilization: The study also reveals high healthcare resource utilization among patients with DRE prior to VNS Therapy, indicating significant unmet needs in this area and further promoting the clinical application of VNS Therapy.
[object Object]
Preview
5.0
12-02Newsfilter
LivaNova Appoints New Global Head of Commercialization for OSA to Drive Market Growth
  • Leadership Change: LivaNova announced that Lucile Blaise will join as Global Head of Commercialization for Obstructive Sleep Apnea (OSA) effective December 1, with her extensive market expertise expected to drive growth in the OSA sector.
  • Industry Experience: Blaise brings over 25 years of leadership experience in the medtech industry, having held various executive roles at ResMed, particularly excelling in market access strategy and commercial team development, which can create new business opportunities for LivaNova.
  • Strategic Goals: Her appointment aims to help LivaNova unlock transformational growth by commercializing its differentiated OSA technology, thereby enhancing patient access to care and improving quality of life.
  • Educational Background: Blaise holds a bachelor's degree in International Business from the University of Sheffield and an MBA from Kedge Business School in France, which will add significant value to her role at LivaNova.
[object Object]
Preview
7.0
11-24Newsfilter
LivaNova's VNS Therapy Reimbursement Increases by 48% Under Medicare
  • Reimbursement Increase: LivaNova's VNS Therapy has been assigned to New Technology APC 1580 under Medicare, with new patient implant reimbursements increasing by approximately 48%, significantly improving hospital economics and reducing barriers to procedure penetration.
  • Service Upgrade: The end-of-service procedures for VNS Therapy have been elevated from Level 4 to Level 5, which is expected to increase hospital reimbursement rates by 47%, encouraging hospitals to more actively offer this treatment to meet the urgent needs of drug-resistant epilepsy patients.
  • Expanded Patient Access: This reimbursement adjustment will significantly enhance access to VNS Therapy, helping more patients, especially those severely underserved in the current healthcare system, to receive treatment.
  • Clinical Effectiveness: The CORE-VNS study demonstrated an 80% median reduction in seizure frequency for focal onset motor seizures at 36 months, providing significant quality of life improvements for patients and further driving market acceptance of this therapy.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is LivaNova PLC (LIVN) stock price today?

The current price of LIVN is 62.75 USD — it has decreased -1.88 % in the last trading day.

arrow icon

What is LivaNova PLC (LIVN)'s business?

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.

arrow icon

What is the price predicton of LIVN Stock?

Wall Street analysts forecast LIVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIVN is 65.83 USD with a low forecast of 55.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is LivaNova PLC (LIVN)'s revenue for the last quarter?

LivaNova PLC revenue for the last quarter amounts to 357.75M USD, increased 12.46 % YoY.

arrow icon

What is LivaNova PLC (LIVN)'s earnings per share (EPS) for the last quarter?

LivaNova PLC. EPS for the last quarter amounts to 0.49 USD, decreased -18.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for LivaNova PLC (LIVN)'s fundamentals?

The market is revising Upward the revenue expectations for LivaNova PLC (LIVN) for FY2025, with the revenue forecasts being adjusted by 0.79% over the past three months. During the same period, the stock price has changed by 11.62%.
arrow icon

How many employees does LivaNova PLC (LIVN). have?

LivaNova PLC (LIVN) has 2900 emplpoyees as of December 13 2025.

arrow icon

What is LivaNova PLC (LIVN) market cap?

Today LIVN has the market capitalization of 3.43B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free